Wide surgical excision is the backbone of therapy for localized soft tissue sarcoma and often produces excellent results. Patients with a marginal resection of disease and high-grade or large tumors are at an increased risk of recurrence. Radiation therapy (external beam or brachytherapy) has been shown to reduce the risk of local recurrence of disease and should be offered to patients with large (>5 cm) or high-grade sarcomas, especially if a wide resection cannot be performed. Use of preoperative versus postoperative radiation therapy should be planned, in consultation with a radiation oncologist and a surgical oncologist, before resection of the sarcoma if possible. Chemotherapy using an anthracycline-and ifosfamidebased regimen may improve disease-free and overall survival rates. Chemotherapy appears to be most beneficial for patients with very large (≥10 cm), high-grade sarcomas of the extremity who are at a high risk of experiencing distant recurrence of disease. The effect of adjuvant chemotherapy on overall survival remains controversial. Research is greatly needed to identify the patients who are most likely to benefit from conventional chemotherapy, improve the treatment of retroperitoneal sarcomas, and identify novel agents that may impact the natural history of high-risk soft tissue sarcoma. (JNCCN 2005;3:207-213) 
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The majority of sarcomas arise in an extremity. Sarcomas are locally invasive, and their propensity to recur locally and in distant sites is related, in a large part, to tumor size and grade. 2 Higher-grade and larger soft tissue sarcomas are more likely to be lethal.
Adding radiotherapy to the surgical management of soft tissue sarcomas improves local control without affecting the risk of distant recurrence of disease or survival and is discussed in more detail in this article. 3 Chemotherapy has also been studied, because metastases develop in 25% to 50% of patients with intermediate-or high-grade sarcomas larger than 5 cm in greatest dimension. Unlike the studies in Ewing sarcoma, osteogenic sarcoma, and pediatric rhabdomyosarcoma, studies of adjuvant chemotherapy for soft tissue sarcoma have not conclusively shown clinical benefit. Possible causes for the lack of clear evidence supporting the use of adjuvant chemotherapy in soft tissue sarcoma include composition of a mixed group of neoplasms with diverse genetic backgrounds, relatively low levels of activity for conventional cytotoxic drugs, and difficulties in conducting large-scale clinical trials in a rare disease in adults. The majority of information about adjuvant chemotherapy for soft tissue sarcoma comes from single-institutional studies and retrospective analyses. Nevertheless, the current data, which include results from a study on the use of an anthracycline and ifosfamide in combination, suggests that certain patients with localized, high-grade sarcomas may derive benefit from systemic therapy.
Adjuvant Radiotherapy
Although radiation therapy does not improve survival in soft tissue sarcoma, neoadjuvant or adjuvant radiation therapy maximizes local control when combined with wide excision. Before the 1970s, amputation was frequently used in the treatment of extremity soft tissue sarcoma, achieving a high rate of local control. 4, 5 Between 1975 and 1981, the National Cancer Institute (NCI) conducted a randomized comparison between amputation and limb-preserving surgery followed by adjuvant radiation therapy in 43 patients. 6 The authors noted 4 local recurrences among the 27 patients in the limbsparing arm and no local recurrence in 16 patients in the amputation cohort. This small NCI trial was extended to 211 patients 7 and remains the basis for limbsparing treatment as the standard of care for extremity soft tissue sarcoma.
The benefits of adjuvant radiation therapy after surgery for soft tissue sarcomas of the extremities have been shown in randomized clinical trials comparing conservative resection alone with resection followed by adjuvant radiation therapy. Yang et al. 3 randomized 91 patients with resected high-grade lesions to receive adjuvant chemotherapy alone or concurrent chemotherapy and radiation therapy. An additional 50 patients with resected low-grade lesions were randomized to receive no further treatment or adjuvant radiation therapy.
Yang et al. found no local treatment failure among the patients with high-grade disease who received radiation therapy, compared with an actuarial local failure risk of 22% at 10 years among patients receiving chemotherapy only. Among patients with low-grade disease, 8 local recurrences were found among patients who did not receive radiation therapy, whereas only 1 patient developed local recurrence after radiation therapy.
In addition, Pisters et al. 8 reported a randomized comparison between surgical resection alone and surgery followed by low-dose-rate interstitial iridium-192 brachytherapy implant delivering 42 to 45 Gy to the tumor bed. 9 For patients with high-grade lesions, 5-year local control rates were 89% with brachytherapy compared with 66% for patients undergoing surgery alone. Interestingly, the benefit of brachytherapy appeared to be limited to patients with high-grade lesions. Five-year local control rates were 75% to 85% with or without adjuvant brachytherapy for patients with low-grade lesions.
Although these trials verify the risk reduction in local recurrence with adjuvant radiation therapy, most experts agree that an appropriately selected subset of "low-risk" patients may be adequately treated with surgery alone. Appropriate surgical management with wide local excision achieving negative surgical margins should result in excellent local control for patients with small (<5 cm), low-grade, superficial tumors. 10 The importance of surgical margin status on local control has been emphasized by numerous authors. 2, [11] [12] [13] Groups have reported low local recurrence rates from the selective application of adjuvant radiation therapy dictated by surgical margin status or tumor location. [14] [15] [16] [17] However, caution must be used in extrapolating justification for omission of radiation therapy from retrospective, single institution reports in which patient selection and other factors may not be completely known, particularly when the benefits of adjuvant radiation therapy on local control have been proven in randomized clinical trials.
The traditional teaching regarding the subclinical extent of local disease in extremity soft tissue sarcoma is that malignant clonogens extend several centimeters beyond the pseudocapsule, resulting in a substantial risk of local recurrence even after resection of the clinically apparent disease. Therefore, surgical protocol dictates that, ideally, the tumor, pseudocapsule, and a rim of several centimeters of normal tissue be excised. Fascial planes and anatomic structures such as bone are believed to be barriers to this extension unless directly invaded by malignant cells. Adjuvant radiation fields are generous, encompassing the preoperative tumor volume as well as the surgical bed within the involved muscular compartment with margins of 5 to 7 cm or more. These large fields are typically treated with an intermediate dose.
They are followed up with one or more successive field reductions that encompass only the preoperative tumor volume or a more limited high-risk volume, such as the region of a positive surgical margin.
Interestingly, the finding that adjuvant brachytherapy treating only the surgical bed with a small 2-cm margin improved local control in high-grade soft tissue sarcomas may challenge the traditional wide-margin approach. 8 Adjuvant radiation therapy doses in most of the described studies have ranged from 60 Gy for resected sarcomas with negative surgical margins to 70 Gy or more for positive surgical margins or gross residual disease. External beam radiation treatments are typically delivered in 1.8 to 2.0 Gy daily fractions to maximize the sparing of late effects, and altered fractionation schemes have generally shown no improvement over conventional fractionation.
Preoperative and postoperative timing for radiation therapy show both potential advantages and potential disadvantages. Preoperative radiation therapy may use smaller treatment fields and lower radiation doses while reducing tumor burden and enabling a more complete surgical resection; however, it may also affect wound healing. Postoperative radiation allows for tailoring the therapy based on the surgical pathology findings, including margin status. However, it may require larger treatment fields and higher radiation doses.
Radiation timing was evaluated by Canadian investigators, who randomized 190 patients with extremity soft tissue sarcomas to undergo surgery followed by postoperative radiation therapy to 50 Gy, followed by a 16 to 20 Gy boost versus preoperative radiation therapy to 50 Gy followed by surgery, with a 16 to 20 Gy boost only for patients with tumor present at resection margins. 18 No chemotherapy was used in this study, and the primary endpoint was rate of wound complications.
With an updated follow-up time to a median of 6.9 years, no statistically significant difference was seen in local control or distant relapse-free, cause-specific, or overall survival. 19 Resection margin was the only significant factor for local control, whereas tumor size and grade were significant for distant relapse-free, cause-specific, and overall survival. Wound complications were more prevalent after preoperative radiation therapy; however, this increased risk was limited to sarcomas of the lower extremity. Late fibrosis and limb edema were significantly increased in the postoperative radiation therapy arm.
Compared with the substantial data guiding the application of adjuvant radiation therapy to extremity soft tissue sarcoma, considerably less evidence and more debate are associated with the role of adjuvant radiation therapy for the 15% of soft tissue sarcomas that are retroperitoneal. Because of location, both surgical and radiation management of these tumors is problematic. Traditional wide surgical margins usually cannot be obtained, and normal tissues, including bowel, spinal cord, kidney, and liver, limit radiation therapy fields, technique, and dose. Postoperative adjuvant radiation therapy is still recommended at many centers and is believed to offer improved local control despite these limitations. 20 However, many experts now advocate the use of preoperative radiation or intraoperative radiation. 21 Preoperative radiation for retroperitoneal sarcomas has the same advantages discussed previously for extremity sarcomas, plus has particular advantages in the abdomen where the tumor displaces dose-limiting structures from high-dose regions and the bowel is more likely to still be mobile, rather than fixed by adhesions as occurs in the postsurgical setting. Therefore, preoperative treatment should result in decreased acute and late radiation toxicity. However, no data yet exist suggesting that preoperative or intraoperative radiation therapy will improve local control or survival for retroperitoneal sarcomas, and the optimal treatment strategy for these challenging tumors remains, to our knowledge, unknown.
Adjuvant Chemotherapy
Many of the early randomized trials of adjuvant chemotherapy for soft tissue sarcoma were compromised by small numbers of patients, inclusion of patients with low-grade or small tumors, or the use of suboptimal doses or types of drugs. As a result, conflicting reports have been published on the benefit of adjuvant chemotherapy in sarcomas of soft tissue. Patients with embryonal or alveolar rhabdomyosarcoma have been shown to benefit from adjuvant therapy and should be treated with active agents and radiation. 22 Pediatric rhabdomyosarcoma is not discussed further. Meta-analyses using abstracted data from published reports of randomized trials suggested that patients treated with adjuvant chemotherapy had an improvement in survival. 23, 24 A meta-analysis that used updated individual patient data involving more than 1,500 patients from 14 randomized trials showed a significant improvement in the local relapse-free interval, distant relapsefree interval, and recurrence-free survival for the chemotherapy-treated patients. 25 An absolute improvement in recurrence-free survival of 10% was seen; however, the improvement in overall survival, which tended to favor the group treated with chemotherapy, was not significant. A 7% improvement in survival at 10 years was reported for the subset of patients with extremity sarcomas who received chemotherapy.
Although data on individual patients were used for the analysis, information regarding tumor grade, size, and status was not available in up to one-third of the cases. This lack may have biased results. In addition, although all of the trials used a doxorubicin-based regimen, the planned total dose of doxorubicin administered varied from 200 mg/m 2 to 550 mg/m 2 among the trials. The use of low doses of doxorubicin may have diluted the observed effect of adjuvant therapy. Ifosfamide was identified as an agent with moderate activity in advanced soft tissue sarcomas, 26, 27 and was recently incorporated into adjuvant therapy trials.
Frustaci et al. 28 were the first to report results from a prospective randomized comparison of ifosfamide administered with an anthracycline adjuvantly versus no chemotherapy in patients with soft tissue sarcoma. One hundred and four patients with sarcoma involving the extremities or proximal limb girdle were randomized to receive 5 cycles of epirubicin (120 mg/m 2 /cycle) and ifosfamide (9 g/m 2 /cycle) or observation after resection and radiation therapy. Malignant fibrous histiocytoma (pleomorphic undifferentiated sarcoma of adults), synovial sarcoma, and liposarcoma accounted for more than 75% of the cases, and the tumor was 10 cm or larger in the majority. Seven patients who were randomized to chemotherapy did not receive treatment; 4 because consent was withdrawn and 3 because of the appearance of pulmonary metastasis before the start of chemotherapy.
At a relatively short follow-up time of 2 years, a significant improvement in disease-free survival of 27% was reported for the group randomized to receive chemotherapy. However, the improvement declined to 13% at 4 years and was no longer significant. A 19% improvement in survival at 4 years for the experimental group was reported. After a median follow-up time of 90 months, the 5-year survival estimate for the chemotherapy group was 66% compared with 46% for the control group (P = 0.04). 29 Subset analyses of the chemotherapy cohort in which patients also received 85% or more of the prescribed total dose of 600 mg/m 2 of epirubicin and 45 g/m 2 of ifosfamide suggested a benefit from higher doses of adjuvant chemotherapy.
A single-institution, non-randomized study of surgery, radiation, and chemotherapy [doxorubicin (60 mg/m 2 /cycle), ifosfamide (6 g/m 2 /cycle), and dacarbazine (1 g/m 2 /cycle) given for 6 cycles] for treatment of high-grade extremity soft tissue sarcomas 8 cm or larger suggested a significant improvement in metastasis-free (P = .0016), disease-free (P = .002), and overall (P = .003) survival from a novel scheduling of chemotherapy interdigitated with radiotherapy compared with a control. 30 The historical control consisted of a group of patients identified in the institution's sarcoma database matched for size and grade of tumor and era of treatment. However, 4 of the 52 control patients received chemotherapy containing doxorubicin and ifosfamide and 8 received other multi-agent chemotherapy. There was a lower percentage of malignant fibrous histiocytoma (MFH) and liposarcoma and a higher percentage of synovial sarcoma and malignant peripheral nerve sheath tumor (MPNST) in the control compared with the experimental group. Liposarcoma and MFH may be associated with a lower risk of sarcoma-specific mortality than synovial sarcoma and MPNST. 31 A joint prospective randomized phase II study of neoadjuvant doxorubicin (50 mg/m 2 /cycle) and ifosfamide (5 g/m 2 /cycle) conducted by the European Organization for the Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada Clinical Trials Group did not show an improvement in disease-free or overall survival for the chemotherapytreated group. 32 Seventy-five patients were enrolled in each arm, but 22% of patients were found to not meet eligibility requirements and 16% had low-grade tumors that probably decreased the power to detect a difference. Moreover, as per design of the trial, patients randomized to chemotherapy received only 3 cycles. This relatively low cumulative total dose of chemotherapy administered may have biased the results. A planned phase III extension was not conducted because of poor accrual to the phase II trial.
Recently, retrospective studies of adjuvant chemotherapy incorporating ifosfamide have shown conflicting results. [33] [34] [35] Patient data were obtained from prospectively managed, large sarcoma databases and medical records. Grobmyer et al. 35 found a benefit from chemotherapy that was most significant for patients with very large tumors. The analysis was restricted to patients with primary, American Joint Commission on Cancer (AJCC) stage 3 soft tissue sarcomas arising in an extremity. Patients diagnosed with Ewing's sarcoma or rhabdomyosarcoma were excluded.
The outcome of 74 patients treated with 4 to 6 cycles of doxorubicin (75 mg/m 2 /cycle) and ifosfamide (6-9 g/m 2 /cycle) followed by surgery were compared to 282 patients who did not receive chemotherapy. The median length of follow-up of survivors was a relatively short 37 months. The use of chemotherapy was associated with a significant improvement in disease-specific but not recurrence-free or metastasis-free survival. In patients with tumors >10 cm in size who received chemotherapy, disease-specific, recurrencefree and metastasis-free survival was improved. In this group, the estimated 3 year disease-specific survival was 83% versus 62% for patients not receiving chemotherapy. In a larger series, Cormier et al. 33 did not find a sustained benefit from chemotherapy. The median follow-up of survivors was 6 years, twice as long as in the Grobmyer study. Younger patients were more likely to have received chemotherapy, and there were minor imbalances in tumor size and histology favoring the no chemotherapy arm. The specifics of the chemotherapy used in the experimental group were not reported, but it is likely that many of the patients did not receive a regimen containing ifosfamide. The subtle biases and use of suboptimal chemotherapy may have contributed to no difference in metastasis-free, disease-specific or overall survival at 5 years. However, Cormier et al. point out the potential hazard of drawing firm conclusions of survival benefit from trials with short follow-up.
The aforementioned studies may be biased by inclusion of multiple sarcoma subtypes. A study by Eilber et al. 34 used the large sarcoma databases available at the Memorial Sloan-Kettering Cancer Center and University of California Los Angeles to limit analysis to patients with primary, AJCC Stage III liposarcoma of the extremity. The outcome of 83 patients treated with a neoadjuvant/adjuvant chemotherapy regimen that included doxorubicin but not ifosfamide was compared to a contemporary cohort of 46 patients treated with surgery with or without radiation.
No difference in disease-specific survival was found between the groups, with a median follow up of over 14 years. The authors did not discuss whether the numbers of patients with pleomorphic, myxoid/round cell, and dedifferentiated liposarcoma were balanced between groups. Pleomorphic liposarcoma has a higher risk of metastasis than myxoid/round cell and dedifferentiated liposarcomas. 36 A comparison of 63 ifosfamide-treated patients with 63 patients who did not receive chemotherapy showed an improvement in disease-specific and distant recurrence-free survival, but not local recurrence-free survival. All of the ifosfamide-treated patients also received doxorubicin and a relatively high median ifosfamide dose of 10 g/m 2 /cycle for a median of 4 cycles. Multivariate analysis showed that treatment with ifosfamide in combination with doxorubicin, smaller tumor size (5-10 cm) and myxoid/round cell or dedifferentiated histology were associated independently with an improved disease-specific survival. The 5-year disease-specific survival of patients with highgrade liposarcoma greater than 10 cm who received ifosfamide and doxorubicin chemotherapy was 89% compared with 58% for the high-risk group of patients who did not receive it (P = 0.0003).
Finally, Issels et al. 37 reported on a phase II trial of 4 cycles of etoposide (250 mg/m 2 /cycle), ifosfamide (5-6 g/m 2 /cycle) and doxorubicin (50 mg/m 2 /cycle) (EIA), followed by surgery and radiation. 38 Regional hyperthermia was applied during chemotherapy. A majority of patients received additional postoperative chemotherapy. With a median follow up of more than 6 years, survival was significantly better in patients with sarcoma that showed a response (defined using radiology and pathology criteria) to chemotherapy. The EORTC is conducting a randomized phase III trial of 8 cycles of EIA with or without regional hyperthermia, surgery, and radiation in high-risk, highgrade soft tissue sarcoma. This trial may show a benefit from hyperthermia, but may not help to clarify the role of ifosfamide-based regimens as adjuvant therapy for soft tissue sarcoma.
Summary
Adjuvant radiotherapy reduces the risk of local recurrence of soft tissue sarcoma and should be offered in most cases in which the sarcoma is resected but a wide margin of normal healthy tissue surrounding the tumor mass could not be obtained. Adjuvant chemotherapy for soft tissue sarcoma remains controversial. Patients with intermediate-or high-grade extremity soft tissue sarcomas larger than 10 cm in size are the most likely to benefit from treatment. Patients with low-grade sarcomas or tumors smaller than 5 cm in size should not be treated routinely with adjuvant chemotherapy because of the low risk of disease recurrence for these patients.
The appropriate recommendations for high-grade tumors 5 to 10 cm in size and for sarcoma arising in the abdomen or retroperitoneum are harder to determine. An anthracycline and ifosfamide-based regimen appears to provide the greatest likelihood of benefit, and the inclusion of dacarbazine or etoposide has not been shown superior to two-drug therapy.
Patients who are offered chemotherapy should be treated with 4 to 6 cycles barring serious complications. The use of neoadjuvant chemotherapy is appealing because the patients with highly chemotherapy-sensitive tumor may be identified, and data are emerging that those patients have a lower risk of relapse. The improvement in disease-free and disease-specific survival from adjuvant chemotherapy is modest at best. Future research on mechanisms of drug resistance, tumor stem cell biology, and inhibitors of critical intracellular events may lead to more effective and less toxic adjuvant treatment for patients with highrisk soft tissue sarcoma.
